In Review: Pharmacy Day at the Capitol was held on March 5. There was a hearing in Senate Commerce on March 6 on SF 205 (Prior Authorization Prohibition of Antineoplastic Cancer Treatment) that PCMA submitted written testimony expressing their opposition to the bill. The bill passed out of committee and was rereferred to the Senate Health and Human Services Committee. The following bills were heard in the Senate Commerce and Policy Committee on March 11: SF 1806 (Prohibiting Certain Formulary Changes During the Plan Year), SF 1876  (formulary), and SF 1877 (point-of-sale rebates). PCMA testified on SF 1877 and submitted written testimony on SF 1876. All the bills were re-referred to the Senate Health and Human Services Committee. The following priority bills were introduced: SF 2176 / HF 2047 (point-of-sale rebates), SF 2075 (Health Plan to Cover Management and Treatment of Obesity), SF 2071 (Prohibit Step Therapy for Insulin), SF 2441 (Prohibit Discrimination Against Providers based on Geographic Location), HF 1808 (copay accumulator), and HF 1838 (Prohibit AI for UM).

Up Next: The following bills are scheduled to be heard in the House Health and Finance Policy Committee on Wednesday, March 19: HF 1652 (Prohibiting Certain Formulary Changes During the Plan Year), HF 1076  (formulary), and HF 1075 (point-of-sale rebates). PCMA plans to testify in opposition to all three bills. PCMA will be hosting a separate call on Tuesday afternoon to discuss the various questions that the Prescription Drug Affordability Advisory Council has been discussing.

If you have any questions, please contact Michelle Mack at mmack@pcmanet.org.